Researchers from the Roswell Park Comprehensive Cancer Center have demonstrated that a normally intracellular peptidase, when administered systemically, bound to the extracellular domain of both HER2 and EGFR, and was effective at killing tumor cells in mouse models of HER2-driven breast cancers.